EP3113760A4 - Applying mechanical force by remote-controlled rotation - Google Patents

Applying mechanical force by remote-controlled rotation Download PDF

Info

Publication number
EP3113760A4
EP3113760A4 EP15759285.8A EP15759285A EP3113760A4 EP 3113760 A4 EP3113760 A4 EP 3113760A4 EP 15759285 A EP15759285 A EP 15759285A EP 3113760 A4 EP3113760 A4 EP 3113760A4
Authority
EP
European Patent Office
Prior art keywords
remote
mechanical force
applying mechanical
controlled rotation
rotation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP15759285.8A
Other languages
German (de)
French (fr)
Other versions
EP3113760A1 (en
Inventor
Erik RENSTROM
Ernst Stetter
Moritz F. KIRCHER
Martin Koch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of EP3113760A1 publication Critical patent/EP3113760A1/en
Publication of EP3113760A4 publication Critical patent/EP3113760A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP15759285.8A 2014-03-04 2015-03-04 Applying mechanical force by remote-controlled rotation Ceased EP3113760A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461947830P 2014-03-04 2014-03-04
PCT/US2015/018746 WO2015134620A1 (en) 2014-03-04 2015-03-04 Applying mechanical force by remote-controlled rotation

Publications (2)

Publication Number Publication Date
EP3113760A1 EP3113760A1 (en) 2017-01-11
EP3113760A4 true EP3113760A4 (en) 2017-08-23

Family

ID=54055841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15759285.8A Ceased EP3113760A4 (en) 2014-03-04 2015-03-04 Applying mechanical force by remote-controlled rotation

Country Status (3)

Country Link
EP (1) EP3113760A4 (en)
CA (1) CA2941635A1 (en)
WO (1) WO2015134620A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6635791B2 (en) 2013-02-20 2020-01-29 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Wide-field Raman imaging apparatus and related method
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
US10688202B2 (en) 2014-07-28 2020-06-23 Memorial Sloan-Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
US10595950B2 (en) 2015-04-28 2020-03-24 University Of Washington Ferromagnetic shaped memory alloy nano-actuator and method of use
US10919089B2 (en) 2015-07-01 2021-02-16 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB2566995B (en) 2017-09-29 2023-01-18 Cotton Mouton Diagnostics Ltd A method of detection
WO2020201812A1 (en) * 2019-04-02 2020-10-08 Wutthinitikornkit Yanee Dynamic clusters of atom particles activated in extracellular fluid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005030986A1 (en) * 2005-07-02 2007-01-11 Ernst Stetter Causing rotation of magnetic beads using superimposed magnetic alternating fields, e.g. for transfection of cultured cells, enzymatic destruction of thrombi, targeted drug release or special sensor formation
EP2671613A2 (en) * 2011-02-01 2013-12-11 Korea University Research And Business Foundation Rotating nanowire and method for inducing cell necrosis using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187082A1 (en) * 2001-06-06 2002-12-12 Chang-Yu Wu Photocatalyst coated magnetic composite particle
US20070196281A1 (en) * 2003-12-31 2007-08-23 Sungho Jin Method and articles for remote magnetically induced treatment of cancer and other diseases, and method for operating such article
RU2472530C2 (en) * 2007-09-24 2013-01-20 Бар-Илан Юниверсити Magnetic metal oxide coated polymer nanoparticles and use thereof
WO2009047587A1 (en) * 2007-10-12 2009-04-16 Ecole Polytechnique Federale De Lausanne (Epfl) Magnetic, paramagnetic and/or superparamagnetic nanoparticles
WO2012027747A2 (en) * 2010-08-27 2012-03-01 The Regents Of The University Of Michigan Asynchronous magnetic bead rotation sensing systems and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005030986A1 (en) * 2005-07-02 2007-01-11 Ernst Stetter Causing rotation of magnetic beads using superimposed magnetic alternating fields, e.g. for transfection of cultured cells, enzymatic destruction of thrombi, targeted drug release or special sensor formation
EP2671613A2 (en) * 2011-02-01 2013-12-11 Korea University Research And Business Foundation Rotating nanowire and method for inducing cell necrosis using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHANG ENMING ET AL: "Alternating Magnetic Fields Trigger Apoptosis by Destruction of Lysosomes with LAMP1-Targeted Nanoparticles", BIOPHYSICAL JOURNAL, vol. 100, no. 3, Suppl. 1, February 2011 (2011-02-01), & 55TH ANNUAL MEETING OF THE BIOPHYSICAL-SOCIETY; BALTIMORE, MD, USA; MARCH 05 -09, 2011, pages 472, XP009194837, ISSN: 1542-0086 *
ZHANG ENMING ET AL: "Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation.", ACS NANO 22 APR 2014, vol. 8, no. 4, 5 March 2014 (2014-03-05), pages 3192 - 3201, XP002771688, ISSN: 1936-086X *

Also Published As

Publication number Publication date
WO2015134620A1 (en) 2015-09-11
EP3113760A1 (en) 2017-01-11
CA2941635A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
EP3240164A4 (en) Actuator
EP3221535A4 (en) Electromechanical lockset
EP3197560A4 (en) Capsule aggregates
EP3175693A4 (en) Remote control apparatus
EP3111304A4 (en) Application launch
EP3197026A4 (en) Rotary actuator
EP3180708A4 (en) Remoting application servers
EP3160559A4 (en) A micro-humidifier
EP3240755A4 (en) Mems driver
EP3125791A4 (en) Fortified high torque device
EP3184498A4 (en) Spacing-maintaining member
EP3135905A4 (en) Rotor
EP3107191A4 (en) Rotor
EP3120250A4 (en) Solid state drive operations
EP3113760A4 (en) Applying mechanical force by remote-controlled rotation
EP3214737A4 (en) Drive device
EP3219589A4 (en) Structural member
EP3181181A4 (en) Microneedle containing retinol or retinol derivative
EP3159538A4 (en) Drive device
EP3153461A4 (en) Mems device
EP3137719A4 (en) Rod rotation apparatus
EP3124817A4 (en) Rotation transmitting device
EP3168499A4 (en) Final drive device
EP3267056A4 (en) Rotation mechanism
EP3158159A4 (en) Mechanical force generator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RENSTROM, ERIK

Inventor name: STETTER, ERNST

Inventor name: KIRCHER, MORITZ, F.

Inventor name: KOCH, MARTIN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61N 2/06 20060101ALI20170713BHEP

Ipc: A61K 9/14 20060101AFI20170713BHEP

Ipc: B82Y 30/00 20110101ALI20170713BHEP

Ipc: C07K 16/30 20060101ALI20170713BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170721

17Q First examination report despatched

Effective date: 20180627

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20200223